Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Heron Therapeutics Inc (NASDAQ:HRTX)

Delayed Data
As of Feb 05
 -1.51 / -7.26%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Heron Therapeutics, Inc. is a pharmaceutical company. It designs and commercializes of polymer technologies for pharmaceutical and other applications. The company develops products using its proprietary Biochronomer polymer based drug delivery technology. Its primary focus is on its product APF530, for the prevention of chemotherapy induced nausea and vomiting. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bioerodible, injectable and implantable delivery systems. Its Biochronomer technology is applicable to a range of therapeutics areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. The company was founded in February 1983 and is headquartered in Redwood City, CA

Contact Information

Heron Therapeutics, Inc.
123 Saginaw Drive
Redwood City California 94063
P:(650) 366-2626
Investor Relations:
(858) 703-6063



Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Barry D. QuartChief Executive Officer & Director
Robert H. RosenPresident, Director & Chief Commercial Officer
Brian G. DrazbaVP, Chief Financial & Accounting Officer
Paul G. MarshallSenior Vice President-Technical Operations
Neil James ClendeninnChief Medical Officer & Senior Vice President